<DOC>
	<DOCNO>NCT01528345</DOCNO>
	<brief_summary>This trial design enroll postmenopausal patient locally advanced metastatic , HER2- HR+ breast cancer amenable curative treatment surgery radiotherapy , whose disease progress prior endocrine therapy . Patients must undergo molecular pre-screening prior entry .</brief_summary>
	<brief_title>Trial Evaluating Dovitinib Combined With Fulvestrant , Postmenopausal Patients With HER2- HR+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman HER2 , HR+ locally advance metastatic breast cancer Progression endocrine treatment Measureable disease per RECIST ECOG 0 , 1 2 Evidence CNS leptomeningeal metastases Previous treatment fulvestrant Previous chemotherapy locally advance metastatic breast cancer Cirrhosis chronic active/persistent hepatitis Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2- , HR+</keyword>
	<keyword>post-menopausal</keyword>
	<keyword>Locally advanced metastatic Breast Cancer ( HER2- , HR+ )</keyword>
</DOC>